Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tevogen Inc. - Common Stock (NQ:TVGN)

6.500 -0.500 (-7.14%)
Streaming Delayed Price Updated: 2:20 PM EDT, Aug 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tevogen Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Tevogen Bio Reaffirms Investor Confidence with Estimated Asset Value Exceeding $10 Billion
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
REPEAT -- Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Unusual volume stocks in Monday's session ↗
Let's have a look at what is happening on the US markets on Monday. Below you can find the stocks with an unusual volume in today's session. 
Via Chartmill
News headline image
Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
REPEAT - Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
REPEAT - Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Receives $1 Million to Accelerate AI-Driven Drug Discovery; Remains Well Capitalized to Execute Growth Strategy
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio to Accept $1 Million Additional Grant Funding for AI Expansion
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Highlights 74% Insider Ownership, Reinforcing Long-Term Vision
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen.AI Applauds U.S. Government’s AI Action Plan; Reaffirms Commitment to Accelerating AI Innovation in Healthcare
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen.AI Receives International Patent Publication for AI Technology Predicting Immunologically Active Peptides
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Signs Letter of Intent for New In-House Cell Therapy Manufacturing Facility
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen.AI Targets Faster Time-to-Market with AI-Powered Patient Matching Following PredicTcell™ Alpha Launch
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen.AI Builds Alpha Version of PredicTcell™ Model with Microsoft and Databricks; Observes Drastic Time Reduction in Target Analysis Translating to Potential Savings of Billions in Drug Development Costs
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen’s New Headquarters, Fully Funded by CEO, Centralizes R&D and AI Teams to Accelerate Innovation
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen CEO Contributes to Build-Out and First-Year Operations of New Headquarters
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Updates on Development of EBV-Specific T Cell Therapy with Support from AI-Powered Target Discovery
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Expands Headquarters Amid Growth of AI and Generics & Biosimilars Initiatives
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks Partnerships
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year; Updated rNPV to Follow
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen to Update on Robust Portfolio Assets, Business Expansion, Partnerships, Limited Tradable Float, High Insider Ownership and Strong Investor Confidence Ahead of June 23 Annual Meeting
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen to Share Direct Registration System (DRS) Process Details Following Increased Shareholder Interest
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
CD8 Technology Signs Letter of Intent for Tevogen Bio’s In-House Manufacturing Facility, Marking First Phase of Up to $50 Million Commitment
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Informs Public Shareholders About DRS Accounts And Differences to Brokerage Accounts
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ’s Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald
From Tevogen Bio Inc
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.